

February 2, 2026

Product Allocations Notice

Dear Valued Customer,

Fresenius Kabi Canada would like to advise that the following products will be placed on allocation effective **February 1, 2026**. Customers are allocated **volumes based on historical monthly demand**. Please see below for details.

DIN	Fresenius Kabi Product Code	MSD Product Code	McKesson Product Code	Product Description	Allocation
02430827	ABU0723	1000560	82092	Linezolid Injection 2 mg/mL, 300 mL Bag	50% Allocation
02139499	C964011	1000737	176445	Magnesium Sulfate Injection, USP 500 mg/mL, 10 mL	125% Allocation
02139561	C1210	1000521	295600	Oxytocin Injection, USP 10 USP units/mL, 10 mL Vial	100% Allocation
02434458	4844001	1000657	91846	Zoledronic Acid for Injection 0.8 mg/mL, 5mL Vial	125% Allocation

Please be advised that allocations for the following products will be updated effective **February 1, 2026**. Contract customers are allocated **volumes based on historical demand**. Please see below for details.

DIN	Fresenius Kabi Product Code	MSD Product Code	McKesson Product Code	Product Description	Allocation
02141019	C360161	1000563	107966	Calcium Gluconate Injection, USP 10% 100 mg/mL, 100 mL Vial	125% Allocation (previously 100%)
02401029	CP1455B1	1000546	46519	Cefazolin for Injection, USP 100 g Bag	50% Allocation (previously 100%)
02409968	CP1456B1	1000552	64206	CefTRIAxone for Injection 100 g Bag	50% Allocation (previously 100%)

We recognize the difficulties and inconvenience that you may encounter as a result of these allocations, and we thank you for your patience and understanding in this matter. If you have any questions or concerns, please do not hesitate to contact your sales representative.

Sincerely,



Joseph Le
 Associate Director, IV Drugs
joseph.le@fresenius-kabi.com

Please scan the QR code to sign up for our email communications.

